Below you'll find a list of all posts that have been categorized as “R&D”
After weeks of voting and over 1000 nominations collected, we are happy to announce the highly nominated companies in each category as voted by you and your peers for the 9th annual Vaccine Industry Excellence (ViE) Awards in the following categories Best Clinical Trial Site AND Network Best Contract Research Organization Best Contract Manufacturing Organization Best Production/Process Development Best Academic Research Team …
In terms of the attendees you will meet at the World Vaccine Congress Washington next month, with weeks to go the event is tracking well ahead of this same point last year. In fact we are estimating a growth in numbers by about 25% overall bringing well over 600 leading vaccine executives to the congress. This means by attending you …
[pullquote type=”right”]“[AMR] is an increasingly serious threat to global public health that requires action across all government sectors and society.” – World Health Organization[/pullquote] It is an alarming fact that AMR (AntiMicrobial Resistance) claims 23,000 Americans lives each year. According to a report commissioned by British Prime Minister David Cameron, AMR could result in 10 million deaths a year by 2050 at a cost of …
The nominations have been counted and we are delighted to announce that the shortlist for the 8th Annual ViE Awards has now been chosen. Join us at the World Vaccine Congress on April 7-9 to meet and celebrate with those deemed worthy of these accolades by booking your ticket today. Hundreds of your colleagues, clients and suppliers voted to choose …
With the 15th World Vaccine Congress on 7 – 9 April in Washington DC only just over a one month away, I conducted an interview to one of our key speakers, Dr Guillaume Leroy, Vice President Dengue Vaccine at Sanofi Pasteur to give you further insight into his exciting talk as well as his top priority vaccine challenges he hopes …
Last week, Advaxis, Inc. (a clinical-stage biotechnology company developing cancer immunotherapies on its proprietary Lm-LLO platform technology), announced that a combined $23 million of purchase agreements was raised, worth approximately 3.1 million shares, at a price of $7.50 per share from several institutional investors. The investors include Adage Capital Management, L.P. Broadfin Capital LLC, Sectoral Asset Management, Cormorant Asset Management and …
VaccineNation welcomes ClinEdge as a guest blogger. Why isn’t your research site being considered for Healthy Volunteer Vaccine Studies? Is it your site? Is it your marketing plan? Over the past five years, the competition for Healthy Volunteer Vaccine Studies has become particularly fierce. Here’s why: Typical Healthy Volunteer Vaccine Studies require patients to come in for only one or …
The world’s leading research company in human viral challenge models, Retroscreen Virology, has announced one of its scientific and medical leadership team will be speaking at 2015 World Vaccine Congress in the USA. Dr Martin Johnson, Senior Medical Director at Retroscreen Virology, is going to be talking about the Retroscreen hVIVO human viral challenge model and how it can be …
When predicting the weather, experts will use informatics tools. These models are used in such a way that we then make decisions and plans based on the output information, and can often avoid getting caught-out by severe storms or take advantage of good weather as a result. So why not use more of these tools in vaccine design? EpiVax has …
1 Event, 7 Conferences at the World Vaccine Congress 2015 The World Vaccine Congress is back for it’s 15th year on April 7-9 in Washington. With over 250 people already signed up to attend, ranging from pharma and biotech, to non-profits and governmental departments, it is set to be another great year. The event has grown for 2015. Not only …